On Tuesday, Tableau Software Inc (NYSE:DATA)’s shares declined -0.42% to $106.04.
PostUp, a leading digital and email marketing solution company, declared recently the availability of its Email Strategy solution, a planned offering in partnership with Tableau Software (NYSE: DATA) and Return Path.
PostUp’s Email Strategy solution empowers email marketers with the ability to easily understand vast amounts of data through the use of clear visuals so that they can determine what is working in their email strategies (in addition to those of their competitors) within one platform.
Tableau Software, Inc., together with its auxiliaries, provides business analytics software products in the United States, Canada, and internationally. The company offers Tableau Desktop, a self-service analytics environment that empowers people to access and analyze data independently; and Tableau Server, a business intelligence platform with data administration, scalability, and security to foster the sharing of data, in addition to improve the dissemination of information in an organization and promote improved decision-making.
WestRock Co (NYSE:WRK)’s shares dropped -0.28% to $63.16.
WestRock Company (WRK) declared that D. Michael Wilson will be the chief executive officer of the company’s specialty chemicals business that is predictable to become a publicly traded company, Ingevity, early next year as a result of a spin-off from WestRock. He will join the company on September 1, 2015.
WestRock Company manufactures and sells paper and packaging solutions for consumer and corrugated markets in North America, South America, Europe, and the Asia-Pacific. It offers folding cartons for use in various food and non-food applications; superior pumps, sprayers, and dispensing closures for home cleaning, healthcare, and beauty and personal care products; and corrugated containers for home appliances, electric motors, small machinery, produce, books, furniture, and other products.
At the end of Tuesday’s trade, Bankrate Inc (NYSE:RATE)‘s shares dipped -4.31% to $10.44.
Mortgage rates pulled back, with the benchmark 30-year fixed mortgage rate sliding to 4.14 percent, according to Bankrate.com’s weekly national survey. The 30-year fixed mortgage has an average of 0.25 discount and origination points.
The average 15-year fixed mortgage dropped to 3.28 percent, while the larger jumbo 30-year fixed mortgage sank to 4.07 percent. For the second week in a row, and just the third time on record, the average rate for the jumbo 30-year fixed rate mortgage is below that of the conforming 30-year fixed mortgage. Adjustable rate mortgages were down, with the 5-year ARM settling at 3.16 percent, the lowest since late April, and the 7-year ARM descending to 3.42 percent.
Bankrate’s national weekly mortgage survey is conducted each Wednesday from data offered by the top 10 banks and thrifts in 10 top markets.
Bankrate, Inc. operates as an online publisher, aggregator, and distributor of personal finance content in the United States and internationally. It aggregates audiences of in-market consumers by providing proprietary, comprehensive, independent, and objective personal finance and related editorial content across various categories, counting mortgages, deposits, insurance, credit cards, senior care, retirement, automobile loans, and taxes.
Raptor Pharmaceutical Corp. (NASDAQ:RPTP), ended its Tuesday’s trading session with -4.38% loss, and closed at $12.89.
Raptor Pharmaceutical Corp. (RPTP) declared financial results for the three and six months ended June 30, 2015 and offered an update on recent corporate developments.
Summary
Global net product sales for PROCYSBI(R) (cysteamine bitartrate) delayed-release capsules were $23.3 million for the second quarter ended June 30, 2015 contrast to $16.3 million for the same period in 2014, representing a growth of 43% year over year.
Raptor stated a net loss on a GAAP basis of $13.9 million for the second quarter, or $0.17 per share.
Cash and cash equivalents were $193.0 million while short-term investments were $27.5 million as of June 30, 2015. Cash balances were bolstered by $92.0 million in net proceeds from an underwritten public offering accomplished in April.
Raptor Pharmaceutical Corp., a biopharmaceutical company, focuses on developing and commercializing life-altering therapeutics that treat debilitating and often fatal diseases. The company offers PROCYSBI, a delayed-release capsule, which is used for the administration of nephropathic cystinosis in adults, in addition to in six years and older children in the United States, in the 28 member states of the European Union, Norway, Liechtenstein, and Iceland. Its clinical development programs comprise RP103 that is used as a treatment for Huntington’s disease; RP103 as a treatment for non-alcoholic fatty liver disease in children; and RP103 as a treatment for mitochondrial disorders, counting Leigh syndrome.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
